Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population

Autor: Elisabeth Pérez-Ruiz, A. Lozano, S. Vázquez Fernández, Raquel Seijas-Tamayo, Ricard Mesia, Miren Taberna, Juan J. Cruz-Hernández, E. del Barco Morillo, R. González Sarmiento, J.C. Adansa Klain, M. Pastor Borgoñón, Javier Fernández-Mateos

Publikováno v: Oral Oncology. 63:38-43

ObjectivesTo examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methodsMulticenter, retrospe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31eae92bad4d6750160d62d70d3b0196
https://doi.org/10.1016/j.oraloncology.2016.10.006

Association of the Cylin D1 G870A polymorphism with laryngeal cancer: are they really related?

Autor: Saime Turan, Canan Cacina, Ilhan Yaylim, Nazli Ezgi Ozkan, Turgay Isbir, Aysegul Verim, Gurbet Korkmaz

Publikováno v: Asian Pacific journal of cancer prevention : APJCP. 14(12)

Background: Cylin D1(CCDN1) is an important regulator of the cell cycle whose alterations are thought to be involved in cancer development. There have been many studies indicating CCDN1 amplification or overexpression in a variety of cancer types. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::719f2c4b238de29fee7621baef7b2c25
https://pubmed.ncbi.nlm.nih.gov/24460344

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.

Autor: Fernández-Mateos J; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain; Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, Spain; Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain., Seijas-Tamayo R; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain., Mesía R; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat, Barcelona, Spain., Taberna M; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat, Barcelona, Spain., Pastor Borgoñón M; Medical Oncology Service, Hospital Universitario Politécnico La Fe, Valencia, Spain., Pérez-Ruiz E; Division of Medical Oncology, Oncology Department, Hospital Costa del Sol, Marbella, Spain., Adansa Klain JC; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain., Vázquez Fernández S; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat, Barcelona, Spain., Del Barco Morillo E; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain., Lozano A; Radiation Oncology Department, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain., González Sarmiento R; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain; Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, Spain; Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain. Electronic address: gonzalez@usal.es., Cruz-Hernández JJ; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain; Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, Spain. Electronic address: ttcc@seom.org.

Publikováno v: Oral oncology [Oral Oncol] 2016 Dec; Vol. 63, pp. 38-43. Date of Electronic Publication: 2016 Nov 12.